Tanaka Osamu, Hayashi Shinya, Sakurai Kota, Matsuo Masayuki, Nakano Masahiro, Maeda Sunaho, Hoshi Hiroaki, Deguchi Takashi
Department of Radiology, Gifu University School of Medicine, Gifu City, Japan.
Radiother Oncol. 2006 Dec;81(3):303-8. doi: 10.1016/j.radonc.2006.10.014. Epub 2006 Nov 27.
To compare the CT-based and CT/MRI fusion-based postimplant dosimetry after permanent prostate brachytherapy and to evaluate the improvement in CT-based dosimetry by physicians with or without experience in using the CT/MRI fusion method.
Thirty-eight consecutive patients agreed to participate in a prospective study. The prostate contours from CT/MRI fusion are the gold standard for determining the prostate volume and dose volume histogram (DVH). CT-based postimplant dosimetries were performed by two physicians. Observer 1 was a radiologist who had never used CT/MRI fusion method for postimplant dosimetric analysis. Observer 2 was a radiation oncologist experienced in postimplant analysis using the CT/MRI fusion method. The prostate dosimetry was evaluated by prostate D90 and V100.
No significant difference was observed in the mean prostate volumes between the two observers and the CT/MRI fusion data. However, the correlation coefficient value for observer 2 (R(2)=0.932) was greater than that for observer 1 (R(2)=0.793). The D90 and V100 values as evaluated by the two observers were significantly underestimated in comparison to those evaluated using the CT/MRI fusion methods. The DVH related parameters were underestimated more frequently by observer 1 than by observer 2: (prostate D90: 99.56% for observer 1, 102.97% for observer 2, 109.37% for CT/MRI fusion. Prostate V100: 88.12% for observer 1, 90.14% for observer 2, 91.91% for CT/MRI fusion).
The difference in the mean value in D90 and V100 by observer 1 was significantly greater than that for observer 2. These findings suggest that the CT/MRI fusion method provides accurate feedback which thereby improves CT-based postimplant dosimetry for prostate brachytherapy.
比较永久性前列腺近距离放射治疗后基于CT和基于CT/MRI融合的植入后剂量测定,并评估有或没有使用CT/MRI融合方法经验的医生在基于CT的剂量测定方面的改进。
38例连续患者同意参与一项前瞻性研究。CT/MRI融合得出的前列腺轮廓是确定前列腺体积和剂量体积直方图(DVH)的金标准。由两名医生进行基于CT的植入后剂量测定。观察者1是一名从未使用CT/MRI融合方法进行植入后剂量分析的放射科医生。观察者2是一名在使用CT/MRI融合方法进行植入后分析方面有经验的放射肿瘤学家。通过前列腺D90和V100评估前列腺剂量测定。
两位观察者得出的平均前列腺体积与CT/MRI融合数据之间未观察到显著差异。然而,观察者2的相关系数值(R(2)=0.932)大于观察者1的相关系数值(R(2)=0.793)。与使用CT/MRI融合方法评估的值相比,两位观察者评估的D90和V100值被显著低估。观察者1比观察者2更频繁地低估DVH相关参数:(前列腺D90:观察者1为99.56%,观察者2为102.97%,CT/MRI融合为109.37%。前列腺V100:观察者1为88.12%,观察者2为90.14%,CT/MRI融合为91.91%)。
观察者1在D90和V100平均值上的差异显著大于观察者2的值。这些发现表明,CT/MRI融合方法提供了准确的反馈,从而改善了前列腺近距离放射治疗基于CT的植入后剂量测定。